We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Cidara Therapeutics, Inc. is one of them. Cidara Therapeutics, Inc. (NASDAQ:CDTX) is a biotechnology company leveraging its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics. Its lead candidate, CD388, is a long-acting antiviral designed to provide universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral replication. In September 2025, CDT ...

Key Points The biotech launched a late-stage trial of a non-vaccine flu preventative. There is a vast addressable market for such a product. 10 stocks we like better than Cidara Therapeutics › Cidara Therapeutics (NASDAQ: CDTX) had some encouraging news to deliver at the end of the trading week, and investors traded the biotech's stock up as a result. It closed Friday nearly 7% higher in price, easily outpacing the 0.6% increase of the bellwether S&P 500 index. Phase 3 trial begins for investigatio ...

Key Takeaways Cidara shares have jumped 217.8% in 2025 so far on progress with its influenza drug candidate CD388.The phase IIb NAVIGATE study met all primary and secondary endpoints across multiple dose levels.The phase III ANCHOR study began ahead of schedule and could support regulatory filing if successful.Shares of Cidara Therapeutics (CDTX) have skyrocketed 217.8% in the year so far, driven by positive updates from the development program of its only clinical-stage pipeline candidate, CD388, for the p ...

- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the first participants have been dosed in its Phase 3 ...

The trial will now include a broader population, such as adults over 65, individuals with high-risk co- morbidities, and those with compromised immune systems. This expansion aims to demonstrate the drug's effectiveness across diverse groups, potentially increasing its market appeal. Currently, CDTX is priced at $88.58, reflecting a 20.53% increase, or $15.09 rise. The stock has fluctuated between $77 and $90.64 today, with the latter being its highest price in the past year. CDTX has a market cap of $2.25 ...

"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

Cidara Therapeutics (NASDAQ:CDTX) added ~15% on Wednesday after the biotech announced an accelerated timeline for a Phase 3 registrational trial designed to evaluate its experimental flu therapy CD388. The update followed an End-of-Phase 2 meeting the company conducted with the ...

BILL O'NEIL ARCHIVES: Analysis Of The Greatest Stocks Of All Time Shares of Cidara Therapeutics (CDTX), which have already rocketed more than 173% this year, surged to a five-year high Wednesday on plans to expand testing for its non-vaccine flu prevention drug. Following a meeting with the Food and Drug Administration, Cidara accelerated plans to start Phase 3 testing by six months. The company's goal is to time out its testing with the flu season in the Northern Hemisphere. The agency also encouraged the ...

- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA approval - Phase 3 study population expanded to include adults over 65 years of age in addition to subjects with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology comp ...

核心观点 - CD388在2b期NAVIGATE试验中显示出对流感预防具有统计学显著性的单剂量长效保护效果，并在H5N1禽流感雪貂模型中证明100%预防死亡的保护效力 [1][2][3] 临床数据 - NAVIGATE 2b期试验纳入超过5000名18-64岁健康未接种疫苗成人，随机接受150mg/300mg/450mg剂量CD388或安慰剂 [2] - 主要终点显示CD388单次皮下注射在24周内对实验室确诊流感具有预防效力 [2] - CD388总体耐受性良好，安全性数据符合预期 [2] preclinical研究 - 雪貂模型中CD388在H5N1病毒接种前24小时以3mg/kg剂量给药实现75%生存率 [3] - 10mg/kg剂量组实现100%生存率，显著减轻体重下降和临床症状 [3] - CD388显著降低雪貂上下呼吸道病毒载量，阻止病毒神经侵袭和全身传播 [3] 产品特性 - CD388采用Cloudbreak®平台开发的药物-Fc偶联物(DFC)，含靶向小分子/多肽与专有人源抗体片段 [6] - 设计为长效抗病毒制剂，通过直接抑制病毒增殖实现单剂预防季节性和大流行性流感 [6] - 2023年6月获FDA快速通道资格认定 [6] 学术交流 - 国际呼吸道病毒学会会议上以最新突破摘要和口头报告形式展示数据 [1][2][3] - 2025年9月19日举办专题研讨会，探讨CD388在健康人群和高危人群中的广谱流感保护潜力 [5] - 研究报告全文将在会议后发布于公司官网"出版物"栏目 [4]